Trial Profile
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Azficel-T for the Treatment of Vocal Fold Scarring and Age-Related Dysphonia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Jun 2021
Price :
$35
*
At a glance
- Drugs Azficel-T (Primary)
- Indications Dysphonia
- Focus Therapeutic Use
- Sponsors Castle Creek Pharmaceuticals
- 30 Jan 2017 Status changed from active, no longer recruiting to completed.
- 07 Jul 2016 Planned End Date changed from 1 Jun 2016 to 1 Apr 2017.
- 08 Jun 2016 Primary endpoint (Voice parameters) has not been met, according to Fibrocell Science media release.